SARS-CoV-2 D614G mutation associated with lower antibody binding

The onset of the COVID-19 pandemic has brought about an international effort to uncover the biology of its causative agent, SARS-CoV-2, and to develop effective and safe antivirals to contain and treat the infection. A new study by a team of researchers in France and Sweden discusses one such study, exploring the relative immunogenicity of the three main structural proteins of the virus.